Sandoz Group (OTCMKTS:SDZNY) Reaches New 12-Month High – Still a Buy?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $93.20 and last traded at $92.8650, with a volume of 5282 shares changing hands. The stock had previously closed at $85.01.

Analysts Set New Price Targets

Separately, Jefferies Financial Group upgraded shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

Sandoz Group Stock Performance

The firm has a fifty day moving average of $78.36 and a 200-day moving average of $69.00. The company has a current ratio of 1.29, a quick ratio of 0.82 and a debt-to-equity ratio of 0.62.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.